These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8737003)

  • 21. Gambling on acamprosate: a case report.
    Raj YP
    J Clin Psychiatry; 2010 Sep; 71(9):1245-6. PubMed ID: 20923626
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.
    Mason BJ; Goodman AM; Chabac S; Lehert P
    J Psychiatr Res; 2006 Aug; 40(5):383-93. PubMed ID: 16546214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
    Johnson BA; O'Malley SS; Ciraulo DA; Roache JD; Chambers RA; Sarid-Segal O; Couper D
    J Clin Psychopharmacol; 2003 Jun; 23(3):281-93. PubMed ID: 12826990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.
    Mann K; Lehert P; Morgan MY
    Alcohol Clin Exp Res; 2004 Jan; 28(1):51-63. PubMed ID: 14745302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment.
    Campanella S; Petit G; Verbanck P; Kornreich C; Noel X
    Neurophysiol Clin; 2011 Jul; 41(3):115-23. PubMed ID: 21784323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
    Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A;
    Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support.
    Morgan MY; Landron F; Lehert P;
    Alcohol Clin Exp Res; 2004 Jan; 28(1):64-77. PubMed ID: 14745303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.
    Kiefer F; Witt SH; Frank J; Richter A; Treutlein J; Lemenager T; Nöthen MM; Cichon S; Batra A; Berner M; Wodarz N; Zimmermann US; Spanagel R; Wiedemann K; Smolka MN; Heinz A; Rietschel M; Mann K
    Pharmacogenomics J; 2011 Oct; 11(5):368-74. PubMed ID: 20585342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of community nurse follow-up when treating alcohol dependence with acamprosate.
    Pelc I; Hanak C; Baert I; Houtain C; Lehert P; Landron F; Verbanck P
    Alcohol Alcohol; 2005; 40(4):302-7. PubMed ID: 15870092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence.
    Laaksonen E; Koski-Jännes A; Salaspuro M; Ahtinen H; Alho H
    Alcohol Alcohol; 2008; 43(1):53-61. PubMed ID: 17965444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
    J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acamprosate.
    Mason BJ
    Recent Dev Alcohol; 2003; 16():203-15. PubMed ID: 12638639
    [No Abstract]   [Full Text] [Related]  

  • 33. Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy.
    Perney P; Lehert P; Mason BJ
    Alcohol Alcohol; 2012; 47(2):133-9. PubMed ID: 22218671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acamprosate campral for alcoholism.
    Med Lett Drugs Ther; 2005 Jan; 47(1199):1-3. PubMed ID: 15599336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.
    Mason BJ; Heyser CJ
    Expert Opin Drug Saf; 2010 Jan; 9(1):177-88. PubMed ID: 20021295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
    Schmidt LG; Smolka MN
    Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acamprosate.
    Kennedy WK; Leloux M; Kutscher EC; Price PL; Morstad AE; Carnahan RM
    Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):363-80. PubMed ID: 20163323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acamprosate: recent findings and future research directions.
    Mann K; Kiefer F; Spanagel R; Littleton J
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1105-10. PubMed ID: 18540918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies.
    Lejoyeux M; Lehert P
    Alcohol Alcohol; 2011; 46(1):61-7. PubMed ID: 21118900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.